With skyrocketing numbers being recorded for the incidence of breast cancer in women, how important does it become to understand the diagnosis and prognosis of the disease. In my previous blog, I clearly outlined how the market is bombarded with innovative game changers such as Immunotherapy, fighting the flaws of chemotherapy.
What if in parallel, I also open your eyes to tools that can help you and your doctor decide whether you even need to undergo chemotherapy. Absolutely, the EndoPredict test, helps to analyze the activity of 12 genes that are involved in the breast cancer. The test provides the result in the form of a EPclin score which is interpreted to understand the recurrence of breast cancer.
Upon testing, if the EPclin Risk score is higher than 3.3287, you are at a higher than 10% risk for recurrence of the cancer. Whereas, if the EPclin Risk score is lower than 3.3287, you are at a lower than 10% risk for recurrence
Additionally, the test also helps to cater to questions such as,
–What are the chances of my cancer coming back in the next ten years?
-Can I forgo taking chemotherapy?
-Will I need hormone therapy after 5 years?
Interesting, how this serves to give us a clear picture of WHAT..WHEN and HOW one could go about its cancer treatment regime! EndoPredict not only answers these questions, but does so precisely with an exact percentage, allowing your doctor and you to decide your treatment strategy for 15 years! Learn more about EndoPredict.